## Congress of the United States

Washington, DC 20515

March 31, 2003

The Honorable Jerry Lewis H 149 Capitol Washington, DC 20515 The Honorable John Murtha 2423 Rayburn HOB Washington, DC 20515

Dear Chairman Lewis and Ranking Member Murtha:

There are 40,000 women who die each year of breast cancer. We do not yet know how to prevent the disease. We do not have an accurate, reliable early detection method. And we do not have a cure for women. This year alone, more than 258,000 women will be diagnosed with breast cancer. This is a serious health issue that must be addressed and must be made a national priority. While we do not have the answers, we do have the best scientists and medical research community in the world. We are confident that with the right investments we can find a cure.

You and your Subcommittee have shown great determination and leadership in the search for answers by funding the Department of Defense (DOD) Peer-Reviewed Breast Cancer Research Program (BCRP) at a level that has brought us closer to eradicating this disease. The DOD BCRP's decade of progress in the fight against breast cancer has been made possible by this Subcommittee's investment in breast cancer research.

To continue this unprecedented progress, we ask that you support a \$175 million appropriation for fiscal year (FY) 2004. Over the past two years, the Conference Committee has cut Defense Health Programs across the board by 15% - bringing funding for the DOD BCRP to \$150 million for FY 2003. Unfortunately, there continues to be excellent science that goes unfunded, which is why we believe that the BRCP should be appropriated \$175 million for FY 2004.

In the span of only ten years, the DOD BCRP has established itself as model medical research program, respected throughout the cancer community for its innovative and accountable approach. The groundbreaking research performed through the program has the potential to benefit not just breast cancer, but all cancers, as well as other diseases.

Since the program's inception, there have been incredible discoveries at a very rapid rate that offer fascinating insights into the biology of breast cancer. The program funded a vital component of the revolutionary work that led to the development of the innovative drug Herceptin, the first monoclonal antibody in the war against cancer. From new methods of extracting breast cancer cells at their earliest stages to unprecedented research into gene/environment interaction to quality of life issues, this program leads the way in generating new approaches to breast cancer prevention, treatment, and early detection. These discoveries have brought into sharp focus the areas of research that hold promise and will build on the investment we have made.

The DOD BCRP is as efficient as it is innovative. In fact, 90% of funds go directly to research grants. The program responds quickly to current scientific advances, and fills gaps by focusing on research that is traditionally under-funded. It is also responsive, not just to the scientific community, but to the public. This is evidenced by the inclusion of consumer advocates at both the peer and programmatic review levels. The consumer perspective helps the scientists understand how the research will affect the community, and allows for funding decisions based on the concerns and needs of patients and the medical community.

The DOD BCRP not only provides a funding mechanism for high-risk, high-return research, but also reports the results of this research to the American people at a biennial public meeting called the "Era of Hope." The 1997 meeting was the first time a federally-funded program reported back to the public in detail not only on the funds used, but also on the research undertaken, the knowledge gained from that research, and future directions to be pursued. The transparency of the BCRP allows scientists, consumers and the American public to see the exceptional progress made in breast cancer research.

At the 2002 Era of Hope meeting, all BCRP award recipients from fiscal years 1998-2000 were invited to report their research findings and many awardees from previous years were asked to present advancements in their research. Scientists reported important advances in the study of cancer development at the molecular and cellular levels. Researchers presented the results of research that elucidates several genes and proteins responsible for the spread of breast cancer to other parts of the body, and, more importantly, reveals possible ways to stop this growth. The meeting, which marked the 10<sup>th</sup> anniversary of the program, also featured grant recipients who are working towards more effective and less toxic treatments for breast cancer that "target" the unique characteristics of cancer cells and have a limited effect on normal cells.

The Institute of Medicine, in an analysis of the program, overwhelmingly supports the BCRP's continuation, stating "the program fills a unique niche among public and private funding sources for cancer research. It is not duplicative of other programs and is a promising vehicle for forging new ideas and scientific breakthroughs in the nation's fight against breast cancer."

There continue to be millions of American women living with breast cancer, as well as their friends and families, who hope that a means of preventing, curing, and better treating this disease will soon be found. To help further the search for answers, we ask that you fund the DOD BCRP at \$175 million for FY 04.

Sincerely,

**NITA LOWEY** 

Member of Congress

TOM DAVIS

Member of Congress

JUDY BIGGERT

Member of Congress

AMES McGOVERN

Member of Congress

Bill Barnell J. Suckelly Ausan Mavis Jan Jan John Charles Strong Dumm Paid H. Dinjohn R. Ut Farla den Owenen Amo Haythan Judy Biggest George Miller Staphan Intho Jose Rabin Euranned Ben Cari Ji-Mi Rost Summed Brown The Mathe Cal Dovery Shaffine Sonaldrulayne Land Eym Steveling geny Kacyka feb Gradley Moren Mc withy

Aue Comp July Jahr Wm. Lacy Clay Ed Case (ma) Ehro Am. Hus. Rob Portman Zee Falge Je Mantal Jin Max Burn John Stake Mohr Dayh Spun John Spelly Berly Down Sirth Party Johns Millell Statistical Suchant Hauselfor Smin Gralfon

me Harmon 1- Holle Quelle Church Zon Vero Benie A. Hungen Wanne Stale Shila Joch Je Boto Filmer James Gremarch Robert And Come Brown Jung-totath Affariale Lewise M. Slaughter T. Felin Honard Colle Rubin Hinginsa Ed Vastor Soloma & Onty Delayrono Tom Lantos Clay Sampa. ABox Jack Zin Zach Warp

John Blavar Link 7. Sandy fust Holt Janny Baldwin John W. Over Duty MFSl Eller ausder int of dich suphardt Welle. Com Foretta andrey Timety V for Damy K. Dani Hono Sucas Ron Krongl Satem Markfor Geolden mbie Oin Redigies Milly With Mill Summer Tot Eng CA. Weth Rappellinger Lois Coups Hilde & Solis

Confr MShire Store Tons Markaul Muchan Frank Palland. Mar fundli Hetrico line of Sup Din Jun Glades Startiful Frank & Sobiendo min notan ly Kely Sue Myrick Jungly Hard Driver Tell Stark Jul Way Veter Davis That Week MMMM Michallompen Man Goldel Jim Langorin Carely M. Carty in Stations

Cawaia Jo Markey Joe Baixton Son you Ode EKstee affected fith Detyrin Steanales Lettinen Sail Pai Willet Lan Benton J-Ch Link Bounhu Wielin & Lipindi Mai Par Barney Kank Jones Russen India & Upt 6 hum Jables Mupe T. Glimest Rosa Ci) Pau Sym Cloulsey Lane Evans Aprel d. Bernan Poline West Honold M. Manzullo Manty Muha Tremostant

Many Peloni Cliff Sky J. Wall Ohis V. Hukene Many Kaptur Jain Obertur Soul Ser. Pek Subd Bart Gordon Rebert J. Mateur Dhall Myret Levelle Royles Pallad Sund Bren Carefys B Holon freak Mille the han Mik Biliakes Itom Orlowne Walta B. Sman B. Mary Chifol John Elwenny Milaspuly Junt Turny Die Sunder Fodd R. Platte Jon Olace

Phil English Julia Carson Willey Berlin Parelson C. Hart Mire Horda Dennis J. Kuremet Kick Larsen Tom alle Garren Seen Jon legrun Fred legter Kany de Bellemman Elist Engl Bobby L. Rush Jose T. Senow Major H. Chu Bill Thomas SU Steffent

